📊 HNGE Key Takeaways
Is HNGE a Good Investment? Thesis Analysis
Hinge Health demonstrates strong business fundamentals with 79.6% gross margins and 50.6% YoY revenue growth, supported by positive $171.4M operating cash flow despite accounting losses. The strong balance sheet and cash generation provide runway, but the -$546.4M operating loss and negative returns on capital require credible evidence of a path to profitability before increasing conviction.
Why Buy HNGE? Key Strengths
- 79.6% gross margin demonstrates strong unit economics and pricing power at core business level
- Positive $171.4M operating cash flow and 29.0% FCF margin despite large accounting losses indicates efficient cash generation
- Strong balance sheet: $208M cash, zero long-term debt, 1.47x current ratio provides substantial strategic flexibility
- Robust 50.6% YoY revenue growth demonstrates strong market demand and successful scaling
HNGE Investment Risks to Consider
- Severe -$546.4M operating loss (-92.9% margin) indicates unsustainable operating expense structure relative to revenue
- Negative ROE (-295.7%) and ROA (-70.9%) demonstrate poor capital efficiency and shareholder value destruction
- Path to profitability unclear; large gap between operating cash flow and net income suggests material non-cash charges masking true operational challenges
Key Metrics to Watch
- Operating margin progression toward profitability and timeline to positive GAAP operating income
- Operating expense ratio trend as business scales and operating leverage emerges
- Free cash flow sustainability and cash burn rate relative to $208M cash reserves
HNGE Financial Metrics
💡 AI Analyst Insight
The 29.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
HNGE Profitability Ratios
HNGE vs Technology Sector
How Hinge Health, Inc. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HNGE Overvalued or Undervalued?
Based on fundamental analysis, Hinge Health, Inc. has mixed fundamental signals relative to the Technology sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HNGE Balance Sheet & Liquidity
HNGE 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Hinge Health, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-8.31 indicates the company is currently unprofitable.
HNGE Growth Metrics (YoY)
HNGE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $100.6M | $341.0K | $0.01 |
| Q2 2025 | $89.8M | -$12.9M | $-0.96 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HNGE Capital Allocation
HNGE SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Hinge Health, Inc. (CIK: 0001673743)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 7, 2026 | 4 | xslF345X06/form4-04072026_080449.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04032026_120423.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_080425.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_080419.xml | View → |
| Mar 24, 2026 | 4 | xslF345X06/form4-03242026_110334.xml | View → |
❓ Frequently Asked Questions about HNGE
What is the AI rating for HNGE?
Hinge Health, Inc. (HNGE) has an AI rating of HOLD with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HNGE's key strengths?
Claude: 79.6% gross margin demonstrates strong unit economics and pricing power at core business level. Positive $171.4M operating cash flow and 29.0% FCF margin despite large accounting losses indicates efficient cash generation.
What are the risks of investing in HNGE?
Claude: Severe -$546.4M operating loss (-92.9% margin) indicates unsustainable operating expense structure relative to revenue. Negative ROE (-295.7%) and ROA (-70.9%) demonstrate poor capital efficiency and shareholder value destruction.
What is HNGE's revenue and growth?
Hinge Health, Inc. reported revenue of $587.9M.
Does HNGE pay dividends?
Hinge Health, Inc. does not currently pay dividends.
Where can I find HNGE SEC filings?
Official SEC filings for Hinge Health, Inc. (CIK: 0001673743) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HNGE's EPS?
Hinge Health, Inc. has a diluted EPS of $-7.77.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HNGE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Hinge Health, Inc. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HNGE stock overvalued or undervalued?
Valuation metrics for HNGE: ROE of -295.7% (sector avg: 22%), net margin of -89.9% (sector avg: 18%). Compare these metrics with sector averages to assess valuation.
Should I buy HNGE stock in 2026?
Our dual AI analysis gives Hinge Health, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HNGE's free cash flow?
Hinge Health, Inc.'s operating cash flow is $171.4M, with capital expenditures of $708.0K. FCF margin is 29.0%.
How does HNGE compare to other Technology stocks?
Vs Technology sector averages: Net margin -89.9% (avg: 18%), ROE -295.7% (avg: 22%), current ratio 1.47 (avg: 2.5).